These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 9490020)

  • 21. The effect of variable domain orientation and arrangement on the antigen-binding activity of a recombinant human bispecific diabody.
    Lu D; Jimenez X; Witte L; Zhu Z
    Biochem Biophys Res Commun; 2004 May; 318(2):507-13. PubMed ID: 15120630
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Computational design of a specific heavy chain/κ light chain interface for expressing fully IgG bispecific antibodies.
    Froning KJ; Leaver-Fay A; Wu X; Phan S; Gao L; Huang F; Pustilnik A; Bacica M; Houlihan K; Chai Q; Fitchett JR; Hendle J; Kuhlman B; Demarest SJ
    Protein Sci; 2017 Oct; 26(10):2021-2038. PubMed ID: 28726352
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Production and characterization of an anti-(MUC1 mucin) recombinant diabody.
    Denton G; Brady K; Lo BK; Murray A; Graves CR; Hughes OD; Tendler SJ; Laughton CA; Price MR
    Cancer Immunol Immunother; 1999 Apr; 48(1):29-38. PubMed ID: 10235486
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mix and match: building manifold binding sites.
    Hoogenboom HR
    Nat Biotechnol; 1997 Feb; 15(2):125-6. PubMed ID: 9035132
    [No Abstract]   [Full Text] [Related]  

  • 25. A single chain Fv specific against Western equine encephalitis virus.
    Xu B; Kriangkum J; Nagata LP; Fulton RE; Suresh MR
    Hybridoma; 1999 Aug; 18(4):315-23. PubMed ID: 10571261
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies.
    Wu X; Sereno AJ; Huang F; Zhang K; Batt M; Fitchett JR; He D; Rick HL; Conner EM; Demarest SJ
    MAbs; 2015; 7(2):364-76. PubMed ID: 25611120
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of the isotype of the light chain on the properties of IgG.
    Montaño RF; Morrison SL
    J Immunol; 2002 Jan; 168(1):224-31. PubMed ID: 11751966
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies.
    Davis JH; Aperlo C; Li Y; Kurosawa E; Lan Y; Lo KM; Huston JS
    Protein Eng Des Sel; 2010 Apr; 23(4):195-202. PubMed ID: 20299542
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Contribution of domain interface residues to the stability of antibody CH3 domain homodimers.
    Dall'Acqua W; Simon AL; Mulkerrin MG; Carter P
    Biochemistry; 1998 Jun; 37(26):9266-73. PubMed ID: 9649307
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cloning the antibody response in humans with inflammatory central nervous system disease: analysis of the expressed IgG repertoire in subacute sclerosing panencephalitis brain reveals disease-relevant antibodies that recognize specific measles virus antigens.
    Burgoon MP; Owens GP; Smith-Jensen T; Walker D; Gilden DH
    J Immunol; 1999 Sep; 163(6):3496-502. PubMed ID: 10477623
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficient heterodimerization of recombinant bi- and trispecific antibodies.
    Schoonjans R; Willems A; Grooten J; Mertens N
    Bioseparation; 2000; 9(3):179-83. PubMed ID: 11105248
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Properties of bispecific single chain antibodies expressed in Escherichia coli.
    Kranz DM; Gruber M; Wilson ER
    J Hematother; 1995 Oct; 4(5):403-8. PubMed ID: 8581376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bispecific human IgG by design.
    Carter P
    J Immunol Methods; 2001 Feb; 248(1-2):7-15. PubMed ID: 11223065
    [TBL] [Abstract][Full Text] [Related]  

  • 34. "Diabodies": small bivalent and bispecific antibody fragments.
    Holliger P; Prospero T; Winter G
    Proc Natl Acad Sci U S A; 1993 Jul; 90(14):6444-8. PubMed ID: 8341653
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs.
    Els Conrath K; Lauwereys M; Wyns L; Muyldermans S
    J Biol Chem; 2001 Mar; 276(10):7346-50. PubMed ID: 11053416
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An engineered bivalent single-chain antibody fragment that increases antigen binding activity.
    Luo D; Geng M; Noujaim AA; Madiyalakan R
    J Biochem; 1997 May; 121(5):831-4. PubMed ID: 9192721
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficient construction of a diabody using a refolding system: anti-carcinoembryonic antigen recombinant antibody fragment.
    Asano R; Kudo T; Nishimura Y; Makabe K; Hayashi H; Suzuki M; Tsumoto K; Kumagai I
    J Biochem; 2002 Dec; 132(6):903-9. PubMed ID: 12473192
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design and Generation of Humanized Single-chain Fv Derived from Mouse Hybridoma for Potential Targeting Application.
    Khantasup K; Chantima W; Sangma C; Poomputsa K; Dharakul T
    Monoclon Antib Immunodiagn Immunother; 2015 Dec; 34(6):404-17. PubMed ID: 26683180
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mono- and bispecific single-chain antibody fragments for cancer therapy.
    Thirion S; Motmans K; Heyligen H; Janssens J; Raus J; Vandevyver C
    Eur J Cancer Prev; 1996 Dec; 5(6):507-11. PubMed ID: 9061285
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Secretion of scFv antibody fragments.
    Gram H; Schmitz R; Ridder R
    Methods Mol Biol; 1998; 103():179-92. PubMed ID: 9680640
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.